Citations 1
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis
Pang, Jiuxia, Yan, Fei , Wu, Lai‐Chu , Al‐Kali, Aref , Litzow, Mark R. , Liu, Shujun , Yang, Xiaojuan, Yang, Xiaojuan, Shen, Na , Peng, Yong , Lee, Robert J.
Oncotarget | April 22, 2016 | Volume: 7 | Issue: 24 | Pages: 36382-36394
